Yibeltal Tenaw, Abitew Dereje Birhanu, Melese Amsalu Birara, Mulu Yared
Department of Epidemiology and Biostatistics, School of Public Health, College of Medicine and Health Science, Bahir Dar University, P.O. Box 79, Bahir Dar, Ethiopia.
Department of Public Health Nutrition, School of Public Health, College of Medicine and Health Science, Bahir Dar University, P.O. Box 79, Bahir Dar, Ethiopia.
Trop Med Health. 2020 Nov 30;48(1):94. doi: 10.1186/s41182-020-00286-9.
HIV and malaria are the leading causes of morbidity and mortality in the developing world including Ethiopia. Globally, HIV-malaria co-infection causes approximately 3 million deaths per year. However, both these infections are preventable if measures are taken on determinant factors. The objective of the study was therefore to assess factors associated with HIV-malaria co-infection among HIV-positive people who lived in Shewarobit district, northeast Ethiopia.
Unmatched case-control study was conducted among people living with HIV (PLWHA) in Shewarobit district from February 28, 2018, to April 30, 2018. The sample size was determined taking the assumption of 95% CI, 85% power, 3:1 control to case ratio, the proportion of PLWHA-malaria coinfection of 22.7%, OR 2.73, and 10% non-response rate. The final sample size was 262 (66 cases and 196 controls). Cases were adults on anti-retroviral therapy and diagnosed positive for malaria by microscopy while controls were adults on anti-retroviral therapy and diagnosed negative for malaria by microscopy in the previous 6 months before the survey.
The median age of cases and controls in years was 35 (IQR = 19) and 38 (IQR = 19) respectively. Variables that had a significant association with HIV-malaria co-infection were non-in-door residual spraying (adjusted odds ratio (AOR) = 4.91; 95% CI 4.03, 15.13), poor perception on the health risk of HIV-malaria co-infections (AOR = 4.11; 95% CI 1.28, 10.17), non-use of insecticidal treated bed nets (AOR = 6.21; 95%CI 2.74, 14.11), non-use of cotrimoxazole prophylaxis (AOR = 2.42; 95% CI 1.11, 5.28), and not received health education on the risk of HIV-malaria interaction (AOR = 4.11; 95% CI 1.24, 4.84).
Provision of cotrimoxazole prophylaxis, sleeping under an insecticidal treated bed net, and indoor residual spraying help to reduce HIV-malaria co-infection-associated morbidity/mortality.
在包括埃塞俄比亚在内的发展中世界,艾滋病毒和疟疾是发病和死亡的主要原因。在全球范围内,艾滋病毒与疟疾合并感染每年导致约300万人死亡。然而,如果针对决定因素采取措施,这两种感染都是可以预防的。因此,本研究的目的是评估埃塞俄比亚东北部舍瓦罗比特地区艾滋病毒呈阳性者中与艾滋病毒 - 疟疾合并感染相关的因素。
2018年2月28日至2018年4月30日,在舍瓦罗比特地区的艾滋病毒感染者(PLWHA)中进行了非匹配病例对照研究。样本量的确定假设为95%置信区间、85%检验效能、3:1的对照与病例比例、PLWHA - 疟疾合并感染比例为22.7%、比值比(OR)为2.73以及10%的无应答率。最终样本量为262例(66例病例和196例对照)。病例为接受抗逆转录病毒治疗且通过显微镜检查诊断为疟疾阳性的成年人,而对照为接受抗逆转录病毒治疗且在调查前6个月通过显微镜检查诊断为疟疾阴性的成年人。
病例和对照的年龄中位数(岁)分别为35(四分位间距[IQR]=19)和38(IQR = 19)。与艾滋病毒 - 疟疾合并感染有显著关联的变量包括未进行室内滞留喷洒(调整后比值比[AOR]=4.91;95%置信区间4.03, 15.13)、对艾滋病毒 - 疟疾合并感染健康风险的认知不足(AOR = 4.11;95%置信区间1.28, 10.17)、未使用经杀虫剂处理的蚊帐(AOR = 6.21;95%置信区间2.74, 14.11)、未使用复方新诺明预防(AOR = 2.42;95%置信区间1.11, 5.28)以及未接受关于艾滋病毒 - 疟疾相互作用风险的健康教育(AOR = 4.11;95%置信区间1.24, 4.84)。
提供复方新诺明预防、使用经杀虫剂处理的蚊帐睡觉以及室内滞留喷洒有助于降低与艾滋病毒 - 疟疾合并感染相关的发病/死亡率。